Our team

Board of Directors

Luis Sánchez-Lafuente

Chairman

Former Chief Executive Officer and co-owner of Laboratorios Gelos, SA. President of AB Biotics, SA

Carles Domènech

Executive chairman

Executive Chairman, CSO and co-Founder of Ability Pharmaceuticals, SL

 

José Manuel Valadés

General secretary

Lawyer, partner and founder of the law firm Alliant Abogados

Miquel Àngel Bonachera

Chief executive officer and co-founder of AB Biotics, SA.
BSc/MSc in biochemistry and MBA.

Sergi Audivert

Chief executive officer and co-founder of AB Biotics, SA. 
BSc/MSc in food technology and MBA.

Sara Secall

Operating Partner & Life Sciences Investment Director of Inveready Asset Management

German Cutillas

Venture Capital Partner at Fitalent (grup Everis)

Roger Piqué

Managing director and co-founder of Inveready Seed Capital SCR.

LATEST NEWS

11.05.2021

Press Release

Ability Pharmaceuticals Announces the Inclusion of the First Patients in a Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as First Line Therapy in Advanced Pancreatic Cancer simultaneously in USA and Europe + info
28.12.2020

Press Release

The Chinese pharmaceutical company SciClone joins the capital of AbilityPharma with an investment commitment of three million dollars + info
16.12.2020

Press Release

The antitumoral drug ABTL0812 shows promising results against neuroblastoma + info
05.11.2020

Press Release

AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain + info
22.10.2020

Press Release

AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + info
22.09.2020

Press Release

ABILITYPHARMA PRESENTS THE RESULTS OF A NEW FIRST-LINE TREATMENT FOR ENDOMETRIAL CANCER + info
09.06.2020

Press Release

AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + info
25.03.2020

Press Release

AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + info
12.09.2019

Press Release

AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG